Xuhui Li

Dr. Xuhui Li


Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Medical Science Monitor
Verified
Journal Article
Closed access
PDF file
HMHou-Shi Ma
Hou-Shi Ma
EWElaine Lu Wang
Elaine Lu Wang
WXWen-Fei Xu
Wen-Fei Xu
SYShozo Yamada
Shozo Yamada
KYKatsuhiko Yoshimoto
Katsuhiko Yoshimoto
XLXuhui Li
Xuhui Li
BACKGROUND:Alteration of DNA methylation of tumor suppressor genes (TSGs) is one of the most consistent epigenetic changes in human cancers. DNMTs play several important roles in DNA methylation and development of cancers. Regarding DNMTs protein exp...

1 January 2014 in International Journal of Endocrinology
Verified
Journal Article
Open access
PDF file
XLXuhui Li
Xuhui Li
EWElaine Lu Wang
Elaine Lu Wang
HZHai-Meng Zhou
Hai-Meng Zhou
KYKatsuhiko Yoshimoto
Katsuhiko Yoshimoto
ZQZhi Rong Qian
Zhi Rong Qian
MicroRNAs (miRNAs) are a class of recently identified noncoding RNAs that regulate gene expression at posttranscriptional level. Due to the large number of genes regulated by miRNAs, miRNAs play important roles in many cellular processes. Emerging evidence indicates that miRNAs are dysregulated in pituitary adenomas, a class of intracranial neoplasms which account for 10–15% of diagnosed brain tumors. Deregulated miRNAs and their targets contribute to pituitary adenomas progression and are associated with cell cycle control, apoptosis, invasion, and pharmacological treatment of pituitary adenomas. To provide an overview of miRNAs dysregulation and functions of these miRNAs in pituitary adenoma progression, we summarize the deregulated miRNAs and their targets to shed more light on their potential as therapeutic targets and novel biomarkers.

18 January 2019 in Oncology Letters
Verified
Journal Article
Closed access
PDF file
YMYicong Ma
Yicong Ma
CFCuiling Feng
Cuiling Feng
JWJingjing Wang
Jingjing Wang
ZCZiwei Chen
Ziwei Chen
PWPeng Wei
Peng Wei
XLXuhui Li
Xuhui Li
Hepatocellular carcinoma (HCC) is a serious threat to human health. Chemotherapy drugs such as cisplatin are widely used in cancer treatment, but can cause severe side effects. Hydroxyl safflower yellow A (HSYA) is a water‑soluble chalcone glycoside substance extracted from safflowers (Carthamus tinctorius L.) that has been reported to inhibit tumor growth with few side effects. The tumor immune microenvironment is crucial for the proliferation and invasiveness of tumor cells, and it is mediated by forkhead box P3‑positive (FOXP3+) regulatory T cells (Tregs) and retinoic acid receptor‑related orphan receptor‑γ (RORγ)‑expressing Th17 cells. FOXP3+ Tregs inhibit immunoreaction and FOXP3 is a key indicator of Tregs. RORγ isoform 2, also known as RORγt, is an important transcription factor in Th17 cells that may promote cancer progression. In the present study, the antitumor effect of HSYA on HCC was investigated, as well as its impact on the tumor immune microenvironment. Following the establishment of a mouse model for HCC, hematoxylin and eosin staining were performed to observe histological changes in liver tumors, and the spleen and thymus were weighed to calculate the spleen and thymus indexes. The proportion of FOXP3+ Tregs in the spleen was determined by flow cytometry, and expression levels of Foxp3 and Rorγt were examined by reverse transcription‑quantitative polymerase chain reaction and western blot analysis. The results of the present study showed that cisplatin inhibited tumor growth, caused weight loss and reduced the immunoreactivity of the mice. HSYA inhibited tumor growth without causing significant weight loss. The proportion of FOXP3‑expressing Tregs in the spleen and the expression of Foxp3 and Rorγt mRNA decreased following treatment with certain doses of HSYA. In conclusion, HSYA inhibited tumor growth without detrimental effects on the weight of the mice, indicating that HSYA may be suitable as a novel therapy for HCC patients.

12 November 2019 in Cell Cycle
Verified
Journal Article
Closed access
WXWen-Fei Xu
Wen-Fei Xu
YMYi-Cong Ma
Yi-Cong Ma
HMHou-Shi Ma
Hou-Shi Ma
LSLong Shi
Long Shi
HMHang Mu
Hang Mu
XLXuhui Li
Xuhui Li
Protein kinase CK2 alpha (CK2α) is involved in the development of multiple malignancies. Overexpression of Y-box binding protein 1 (YBX1) is related to tumor proliferation, drug resistance, and poor prognosis. Studies have demonstrated that both CK2 and YBX1 could regulate the PI3K/AKT pathway. In addition, we predicted that CK2 might be the upstream kinase of YBX1 through the Human Protein Reference Database (HPRD). Herein, we hypothesize that CK2 may interact with YBX1 and they regulate the PI3K/AKT signaling pathway together. Expressions of CK2α and YBX1 in cancer cell lines were evaluated by immunoblotting. The results showed that CK2α could regulate the expression of YBX1 at the transcriptional level, which is dependent on its enzymatic activity. Synergistic effects of PI3K/AKT pathway inactivation could be observed through combined inhibition of CK2α and YBX1, and YBX1 was required for CK2α-induced PI3K/AKT pathway activation. Further results demonstrated that CK2α could interact with YBX1 and PI3K/AKT antagonist decreased cell resistance to doxorubicin induced by co-activation of CK2α and YBX1. These results indicated that combined inhibition of CK2α and YBX1 showed synergistic effects in inactivating the PI3K/AKT signaling pathway and may be one of the mechanisms involved in tumor growth and migration.

1 March 2011 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
XLXuhui Li
Xuhui Li
ZCZhe Chen
Zhe Chen
YGYan-Song Gao
Yan-Song Gao
Yong-Bin YanYong-Bin Yan
Yong-Bin Yan
FZFang Zhang
Fang Zhang
HZHai-Meng Zhou
Hai-Meng Zhou

12 August 2023 in Peptides
Verified
Journal Article
Closed access
WFWang Feifei
Wang Feifei
SWSu Wenrou
Su Wenrou
KSKang Sining
Kang Sining
ZSZhu Siyu
Zhu Siyu
FXFu Xiaolei
Fu Xiaolei
XLXuhui Li
Xuhui Li